Cipla actions: Analysts turn to Cipla after a Revlimid patent solution; see almost 30% rally

According to the short-term firm, the gRevlimid compromise is positive for Cipla’s shares since the market no longer affected potential earlier this opportunity.

Shares of Cipla Ltd ended nearly one percent down today in BSE after the company announced the settlement of its lawsuit with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, in relation to patents for Revlimid (lenalidomide). Most of the research and brokerage houses are optimistic on Cipla shares and see more than 26%. According to a BSE filing, in order to resolve all outstanding claims in the lawsuit, Celgene has agreed to provide Cipla with a license to Celgene’s patents necessary to produce and sell certain volume-limited quantities of unbranded lenalidomide in the United States beginning on a confidential date. .

Read also: ‘Neutral’ in Cipla, with a good place to deliver 24% of CAGR revenue

Analysts at Edelweiss Research welcomed the compromise as it gave visibility to FY23 / 24E revenues. For Cipla, the short firm assumed a peak market share of 10% in the limited volume. It revised its target price to Rs 945 from Rs 910 per one, earlier, which implies a height of almost 20 per cent from the previous closing. It recommended ‘buying’ Cipla shares.

According to JM’s Financial Services, the terms of the settlement offered to Cipla appear similar to those offered to Dr. Reddy and Alvogen with the agreed volume restrictions remaining confidential.

It was also recommended to ‘buy’ the shares with a target price of 1000 rupees per one. Cipla will need to jump 26.7 percent from the previous end to reach the target price set by the brokerage. It added that with Cipla reaching an orderly market share in gProventil, US growth is now expected to gain market share from other Albuterol inhalers with Proventil’s share in the overall Albuterol market growing to 10% and a favorable competitive landscape. Perrigo’s exit will likely be a key short-term tailwind.

BOB Capital Market is also bullish on Cipla stock, with a price target of Rs 900, 14 per cent opposite of previous closing. According to the brokerage firm, the gRevlimid compromise is positive for Cipla’s shares, as the market was no longer affected by a possible position earlier this opportunity. “This enhances confidence in Cipla’s ability and focus on maximizing the value opportunity in complex general generations,” he added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, Mutual Fund portfolio, calculate your tax rate with Income Tax Calculator, know the Best Winners, Most Losers and Best Stock Finance of the market. Like us on Facebook and follow us on Twitter.

Financial Express is now at Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.